



I. Epidemiological profile

Population	2014	%
High transmission (>1 case per 1000 population)	223 000	86
Low transmission (0-1 cases per 1000 population)	37 800	14
Malaria free (0 cases)	0	0
Total	261 000	

Parasites and vectors			
Major plasmodium species: <i>P. falciparum</i> (47%), <i>P. vivax</i> (52%)			
Major anopheles species: <i>An. darlingi</i>			
Programme phase: Control			
Reported confirmed cases:	448	Estimated cases, 2013:	[940-3400]
Reported deaths:	0	Estimated deaths, 2013:	<10

II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted
ITN	ITNs/LLINs distributed free of charge	Yes	2012
	ITNs/LLINs distributed to all age groups	Yes	2012
IRS	IRS is recommended	Yes	-
	DDT is authorized for IRS	No	-
Larval control	Use of larval control recommended	Yes	-
IPT	IPT used to prevent malaria during pregnancy	N/A	-
Diagnosis	Patients of all ages should receive diagnostic test	Yes	-
	Malaria diagnosis is free of charge in the public sector	No	-
Treatment	ACT is free for all ages in public sector	Yes	-
	Sale of oral artemisinin-based monotherapies	Never allowed	-
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	No	-
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	-
	G6PD test is a requirement before treatment with primaquine	Yes	-
	Directly observed treatment with primaquine is undertaken	No	-
	System for monitoring of adverse reactions to antimalarials exists	Yes	-
Surveillance	ACD for case investigation (reactive)	No	-
	ACD of febrile cases at community level (pro-active)	No	-
	Mass screening is undertaken	No	-
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	-
	Uncomplicated <i>P. vivax</i> cases routinely admitted	Yes	-


Antimalaria treatment policy	Medicine	Adopted
First-line treatment of unconfirmed malaria	-	-
First-line treatment of <i>P. falciparum</i>	AL	-
Treatment failure of <i>P. falciparum</i>	AQ+PG	-
Treatment of severe malaria	Artesunate IV + relais AL	-
Treatment of <i>P. vivax</i>	CQ+ PQ après dosage G6PD	-
Dosage of primaquine for radical treatment of <i>P. vivax</i>	0.50 mg/kg (14 d)	-
Type of RDT used	<i>P. f</i> + all species (Combo)	-

Therapeutic efficacy tests (clinical and parasitological failure, %)							
Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species
-	-	-	-	-	-	-	-

Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)					
Year	Pyrethroid	DDT	Carbamate	Organophosphate	Species/complex tested
2010-2014	-	-	-	-	-

III. Financing

Sources of financing




Financing by intervention in 2014


No data reported for 2014

IV. Coverage


ITN and IRS coverage




Cases tested and treated in public sector



Cases tracked




Test positivity




V. Impact

Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths



Impact: On track for >75% decrease in incidence 2000-2015